Travere Q1 net product sales $75.9M; FILSPARI sales $55.9M, net loss narrows to $0.47/share

Travere Therapeutics, Inc.

2025-Q1 EPS reported -$0.47 revenue$81,732,000

Net product sales $75.9M (1Q25) vs $40.0M (1Q24), driven by FILSPARI launch.
FILSPARI U.S. net sales $55.9M; 703 new patient start forms in quarter.
Net loss $41.2M ($0.47/share) vs $136.1M ($1.76/share) YoY; adj. net loss $16.9M.
Cash & securities $322.2M; sNDA submitted for full approval of FILSPARI in FSGS.
EU and UK converted FILSPARI to full approval in IgAN; $17.5M milestone from CSL Vifor expected Q2.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.